Indivior appoints Mark Crossley as new CEO

– UK, Slough –  Indivior PLC (LON: INDV) today announced the appointment of Mark Crossley as CEO, effective today, succeeding Shaun Thaxter who is stepping down as CEO and Executive Director.

“Indivior’s vision is to ensure patients all around the world have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Mark is a proven leader with a broad strategic and financial skillset and a deep understanding of the Company’s guiding principles. The Board has full confidence in his ability to drive Indivior forwards and to pursue its vision for the benefit of all stakeholders.” said Interim Chair, Daniel Tassé.

He added”: “Shaun has played a key role since the formation of Indivior and on behalf of the Board we thank him for his significant contributions to Indivior and, in particular, his efforts to advance addiction treatment across our global communities. Indivior has a strong culture across all fronts of the business and I and the Board look forward to supporting Mark, the executive team and all of our colleagues in the months and years ahead.”

Ryan Preblick, currently SVP Global Financial Planning and Analysis Commercial Operations, has been appointed interim CFO. As an interim appointee, Mr. Preblick will not be appointed as an Executive Director.

About Mark Crossley

Mr. Crossley has been Chief Financial and Operations Officer and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.

CEO of Indivior commented: “I am honoured to have been appointed as Chief Executive Officer of Indivior as we continue our work to change patients’ lives by developing medicines to treat addiction and serious mental health illnesses. In recent years, the Group has made excellent strategic progress on life-transforming treatments with the launch of SUBLOCADE and PERSERIS. There remains a very significant opportunity for Indivior in the years ahead, and I look forward to working with the Board to deliver the full potential of our key assets, to resolve outstanding investigations and litigations as expeditiously as possible, and to ensure that we continue to play a leading role in helping patients, doctors, and communities fight the human crisis of opioid addiction. Finally, I would like to take a moment to thank Shaun for his leadership at Indivior and significant contributions within the addiction treatment community.”

About Indivior

Indivior is a global speciality pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.